COMMUNIQUÉS West-GlobeNewswire
-
Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
20/02/2018 - 13:01 -
Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
20/02/2018 - 13:00 -
Blood donors urgently needed to meet patient needs leading up to spring break
20/02/2018 - 13:00 -
Discovery Point Retreat Offers Drug and Alcohol Rehabilitation in Texas
20/02/2018 - 13:00 -
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20/02/2018 - 13:00 -
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
20/02/2018 - 13:00 -
Urgent besoin de donneurs d’ici la semaine de relâche
20/02/2018 - 13:00 -
AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
20/02/2018 - 13:00 -
Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene
20/02/2018 - 13:00 -
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
20/02/2018 - 13:00 -
Zomedica to Participate in the Bank of America Merrill Lynch Animal Health Summit
20/02/2018 - 12:55 -
Capital Senior Living Corporation Announces That Jeremy D. Falke Has Joined as Senior Vice President of Human Resources
20/02/2018 - 12:45 -
Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
20/02/2018 - 12:30 -
Dynavax Secures $175 Million in Non-Dilutive Debt Financing
20/02/2018 - 12:30 -
Transactions in relation to share buyback program
20/02/2018 - 12:23 -
Company Announcement No. 6/2018
20/02/2018 - 12:00 -
BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27
20/02/2018 - 12:00 -
Comfort Recovery Now In-Network with Humana, Aetna, and Beacon Health Options
20/02/2018 - 12:00 -
Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
20/02/2018 - 12:00
Pages